Literature DB >> 10197293

Assessment of QTc prolongation for non-cardiac-related drugs from a drug development perspective.

P L Bonate1, T Russell.   

Abstract

It is increasingly likely that non-cardiac-related drugs will need to be routinely analyzed for their ability to prolong cardiac repolarization. This leads to potential problems for drug companies in general and statisticians in particular. A number of issues immediately arise in regard to answering the question, "Does drug X prolong cardiac repolarization?" These include identifying what is the desired outcome, what is the dependent variable, and what analysis method should be used. The purpose of this article is bring to to light some of the issues regarding the analysis of QTc data, the advantages and disadvantages of these analysis methods, and some general recommendations.

Mesh:

Substances:

Year:  1999        PMID: 10197293     DOI: 10.1177/00912709922007912

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction.

Authors:  Corina Dota; Bo Skallefell; Nils Edvardsson; Gunnar Fager
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

Review 2.  The significance of QT interval in drug development.

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

Review 3.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

4.  Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions.

Authors:  Anne S Y Chain; Jeanne P Dieleman; Charlotte van Noord; Albert Hofman; Bruno H Ch Stricker; Meindert Danhof; Miriam C J M Sturkenboom; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 5.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs.

Authors:  Igor Diemberger; Giulia Massaro; Marta Cubelli; Daniela Rubino; Sara Quercia; Cristian Martignani; Matteo Ziacchi; Mauro Biffi; Alessandra Bernardi; Nicoletta Cacciari; Claudio Zamagni; Giuseppe Boriani
Journal:  Eur J Clin Pharmacol       Date:  2015-06-02       Impact factor: 2.953

Review 7.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation.

Authors:  Vladimir Piotrovsky
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 8.  The role of concentration-effect relationships in the assessment of QTc interval prolongation.

Authors:  Nicholas P France; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

9.  Designing and interpreting the results of first-time-to-man studies.

Authors:  A A Patat
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.